Infection News

Talicia, a novel drug for the treatment of Helicobacter pylori, achieved positive top-line results in a phase 3 study, according to a press release from RedHill Biopharma, the manufacturer.

Sovaldi-based therapy was safe and effective in as short as 8 weeks for treating hepatitis C in patients with cancer and may induce remission of non-Hodgkin’s lymphoma, according to a recently published study.

Antios Therapeutics completed a $25 million oversubscribed Series A financing to develop ATI-2173, an oral drug candidate for treating patients with hepatitis B and potentially coinfected with hepatitis D, according to a press release.

On-treatment improvement of MELD scores correlated with reduced risk for all-cause mortality and hepatic events among patients with chronic hepatitis B and cirrhosis, according to a recently published study.

Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.

Surveillance data show that norovirus outbreaks caused by a single genotype, GII.4, and those occurring in health care facilities include higher rates of severe outcomes — findings that should guide vaccine development, researchers said.

Mavyret demonstrated 97% sustained virologic response in a large, real-world cohort of patients with hepatitis C over an 8-week course and extended 12-week to 16-week courses, according to recently published data.

NEW YORK — According to a presentation at the annual Infectious Diseases in Children Symposium, 61% of all children in the United States attend some type of out-of-home child care. Exclusions from school or child care are often unnecessary — especially for diarrheal illness — and they add to the burden of lost work time, the presenter said.

The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.

Results from a retrospective review of patients infected with hepatitis C in childhood revealed that those with perinatal infection developed cirrhosis earlier than other risk groups, according to a recently published study.